{
  "model": "chatgpt-gpt-5.3-codex",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "result": {
    "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
    "thoughts": "**Verifying JSON validity**\n\nI need to ensure the JSON is valid for study_overview, claim_audit, and public_summary, which is now fixed. We should verify that public_summary's plain language summary fits the length requirement of 180-1200 characters, likely around 650. The headline length should also be between 20-120 characters, which seems good. I've already rewritten public_summary due to the previous JSON issue. Now, I'll follow the rule to finish after writing the required files and have valid JSON, while avoiding loops. I’ll respond with a checklist.",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Reading task document**\n\nI need to read the TASK.md file using the appropriate tool. It seems that there are two phases to follow for this process, which gives me a little structure. I'll go ahead and use the reading tool to proceed, ensuring I cover everything necessary in each phase. It's essential to gather the right information from the document to complete my task effectively. Let's get started!",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_gK9SGpb2qxLNd6Th8xxRg9Rv"
          }
        ],
        "usage": {
          "promptTokens": 571,
          "cachedTokens": 0,
          "responseTokens": 31,
          "thinkingTokens": 21,
          "totalTokens": 623
        },
        "costUsd": 0.00172725
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Reviewing report requirements**\n\nI need to read the relevant report and schemas first. In Phase 1, my goal is to digest both the report and schemas to draft the necessary data. I'll utilize the tools available to me to pull relevant information. To keep organized, I should also list the schemas directory so I know what I have access to. This way, I can reference everything I need while moving through the task efficiently.",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_UdRMFAyipxqSDdwvNnRbnIRP"
          }
        ],
        "usage": {
          "promptTokens": 1019,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 29,
          "totalTokens": 1092
        },
        "costUsd": 0.0028052499999999996
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_3fUUtDVEVxCJxVWi4CA5alHu"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_yMzXmvT6HbpyvdlB1RIo2PJR"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_kDsSUZPxvpNaqsW6NVlG6sVF"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_l1zv7PkulOSpUqej8LNaAIO6"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_pvo0z6uJCOOCwoiTehLc9i51"
          }
        ],
        "usage": {
          "promptTokens": 1092,
          "cachedTokens": 0,
          "responseTokens": 165,
          "thinkingTokens": 0,
          "totalTokens": 1257
        },
        "costUsd": 0.004221
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "output",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.json\npublic_summary.json\nquantitative_findings.json\nstudy_overview.json",
            "callId": "call_7UQMPQuAZZS5lVXHuZWFUDCy"
          }
        ],
        "usage": {
          "promptTokens": 5280,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 428,
          "totalTokens": 5752
        },
        "costUsd": 0.015848
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Inspecting outputs for schema**\n\nI see that outputs already exist, but I need to ensure they're correctly formatted. The task specifies that I should produce the required JSON outputs, but I have a rule to finish only after all necessary files are written. First, I should check the existing output files to see if they match the schema. It’s important to make sure everything lines up correctly!  I'll dive into those files and inspect them now.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_dHlZvGTFOSPATCX13YzaX2jY"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_F8RpVHZEQwfYQynJv1GqNm9Z"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_nv9zV7u4xvEJwThvnsC8Mx50"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: {}",
            "callId": "call_EYq4nLwMRGU38yXAiUnWUzSL"
          }
        ],
        "usage": {
          "promptTokens": 5349,
          "cachedTokens": 0,
          "responseTokens": 137,
          "thinkingTokens": 48,
          "totalTokens": 5534
        },
        "costUsd": 0.01195075
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Writing JSON files**\n\nI need to write files using tools, specifically with `write_file`. I want to draft the JSON carefully and ensure I’m not accidentally overwriting any existing output since they'll just be empty. I should also pay attention to the relative paths. I'll proceed with the writing in phase 2 and consider if I should use parallel processing. Each quote must be exact, and I’ve got specific lines to ensure accurate citations. Let's focus on crafting the content strings!**Selecting evidence for claims**\n\nI'm working on some claim examples that involve intratumoral mRNA vaccination, which induces type I interferon signaling and enhances antigen presentation. For C01, I need 2-3 specific quotes: one from line 42 about mechanistic action, one from line 44, and maybe a quantitative line from 29. Quotations must be exact snippets from the report, especially for the table values. For C02, I’ll note the combination with anti-PD-L1 and mention the retrospective study's moderate strength and its confounding factors.**Drafting claims with evidence**\n\nFor claim C03, I’m focusing on sensitization, which relies on type I IFN and the mRNA component. If we block IFNAR1, the benefits are eliminated, but lipid particles without mRNA do not show this effect. The evidence is strong for mechanistic explanations in models, with some caveats regarding mice. Moving to claim C04, human findings emphasize the need for prospective randomized studies before clinical changes, and the evidence supports a strong caution about limitations. I’ll pull quantitative findings into clear interpretations, focusing on control statements from line 38, too.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory tumor state that improves sensitivity to immune checkpoint blockade (anti-PD-L1)?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Murine tumor models treated with intratumoral mRNA vaccine in combination with anti-PD-L1, pooled across repeat experiments to assess anti-tumor efficacy.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (single agents/vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched murine controls including vaccine only, ICI only, and vehicle arms pooled across experiments to benchmark baseline activity and specificity of effects.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, stratified by prior SARS-CoV-2 mRNA vaccination status for outcome comparison.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used for survival comparison under ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for survival under ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_ATeTsj73sYTpwSmHB4k2qXaj"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination is associated with broader antigen display in the tumor immunopeptidome.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expands substantially after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"In the retrospective cohort, vaccinated patients had statistically improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors show a marked induction of a type I interferon response after mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 pathway activity increases, supporting a mechanistic rationale for checkpoint blockade combination.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination therapy increases CD8+ T-cell infiltration relative to baseline.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_CCFIGVVkmQPGKwBuljRlcyH0"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination induces type I interferon signaling and is associated with expanded antigen presentation on MHC-I.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"The report summarizes mechanistic steps, but notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The combined intervention improves tumor control in mice and aligns with better outcomes in a retrospective human cohort stratified by SARS-CoV-2 mRNA vaccination status.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, so alignment with better outcomes does not establish causality.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The reported sensitization effect is conditional on the mRNA-triggered type I interferon pathway, based on particle controls and IFNAR1 blockade results.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"These perturbation controls are described in the report, but the overall findings are from preclinical systems and may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Prospective randomized studies are required before changing clinical protocols based on the reported tumor-sensitization effects.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        },\n        {\n          \"quote\": \"The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.\",\n          \"line_ref\": \"L55\"\n        }\n      ],\n      \"caveat\": \"This is a cautious interpretive conclusion; it does not quantify how large a benefit would be expected in a future randomized trial.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_sxePLsVMEAzB9xJ2AyudVqwZ"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may boost response to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting tumor control in some people, but many tumors do not respond because they are not well recognized by the immune system. This study asks whether putting an mRNA vaccine directly into a tumor can trigger a strong local innate immune reaction—especially type I interferon signaling—that makes the tumor more visible to immune cells and more susceptible to anti-PD-L1 therapy. In mouse tumor models, the authors report that intratumoral mRNA vaccination broadens the set of tumor-derived peptides presented on MHC-I and increases signs of immune activation. In a separate retrospective analysis of metastatic patients treated with ICIs, outcomes differed when patients were grouped by prior SARS-CoV-2 mRNA vaccination status (reported p=0.01). Because the human data are retrospective and non-randomized, the work supports a mechanistic hypothesis but does not yet justify changes to clinical practice without prospective randomized trials.\",\n  \"what_is_new\": [\n    \"Links intratumoral mRNA vaccination to broader antigen presentation in tumors (immunopeptidome and MHC-I peptidome).\",\n    \"Proposes a mechanistic chain from type I interferon signaling to increased tumor visibility and PD-L1 pathway activity.\",\n    \"Adds a retrospective human cohort comparison stratified by prior SARS-CoV-2 mRNA vaccination status during ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so confounding could explain some or all of the survival difference.\",\n    \"Vaccination timing relative to ICI initiation varied, complicating interpretation of cause and effect.\",\n    \"Mouse model results may not translate directly to all human tumor types and treatment histories.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) so T cells can attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"Anti-PD-L1\",\n      \"definition\": \"A type of ICI antibody that targets PD-L1, aiming to restore anti-tumor T cell activity in the tumor environment.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of innate immune signaling molecules that can induce antiviral-like inflammation and alter antigen presentation in tissues.\"\n    },\n    {\n      \"term\": \"Antigen presentation (MHC-I)\",\n      \"definition\": \"The process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal proteins.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The collection of peptides presented by a tissue on MHC molecules, reflecting what the immune system can \"see\".\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would intratumoral mRNA vaccination improve ICI responses in a prospective randomized clinical trial?\",\n    \"Which tumor types, disease stages, or prior treatments would be most likely to benefit from this strategy?\",\n    \"What is the optimal timing of vaccination relative to starting checkpoint blockade to maximize benefit and safety?\",\n    \"Could repeated intratumoral dosing maintain benefit without excessive inflammation or immune-related toxicity?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_qtv5MlDXicjMotbCRZERmiQi"
          }
        ],
        "usage": {
          "promptTokens": 5528,
          "cachedTokens": 4480,
          "responseTokens": 3309,
          "thinkingTokens": 1093,
          "totalTokens": 9930
        },
        "costUsd": 0.064246
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Ensuring JSON validity**\n\nI need to make sure that the JSON is valid, especially focusing on quotes in the immunopeptidome glossary. It looks like there are unescaped quotes that need attention; they should be escaped since they're inside a JSON string. Additionally, I need to check that other files align with the necessary schemas. To do this efficiently, I plan to quickly read the output of the file public_summary.json for any parsing issues.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 250
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccination inside tumors may boost response to checkpoint immunotherapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting tumor control in some people, but many tumors do not respond because they are not well recognized by the immune system. This study asks whether putting an mRNA vaccine directly into a tumor can trigger a strong local innate immune reaction—especially type I interferon signaling—that makes the tumor more visible to immune cells and more susceptible to anti-PD-L1 therapy. In mouse tumor models, the authors re\nL4:   \"what_is_new\": [\nL5:     \"Links intratumoral mRNA vaccination to broader antigen presentation in tumors (immunopeptidome and MHC-I peptidome).\",\nL6:     \"Proposes a mechanistic chain from type I interferon signaling to increased tumor visibility and PD-L1 pathway activity.\",\nL7:     \"Adds a retrospective human cohort comparison stratified by prior SARS-CoV-2 mRNA vaccination status during ICI treatment.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding could explain some or all of the survival difference.\",\nL11:     \"Vaccination timing relative to ICI initiation varied, complicating interpretation of cause and effect.\",\nL12:     \"Mouse model results may not translate directly to all human tumor types and treatment histories.\",\nL13:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) so T cells can attack tumors more effectively.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Anti-PD-L1\",\nL22:       \"definition\": \"A type of ICI antibody that targets PD-L1, aiming to restore anti-tumor T cell activity in the tumor environment.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Type I interferon\",\nL26:       \"definition\": \"A family of innate immune signaling molecules that can induce antiviral-like inflammation and alter antigen presentation in tissues.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"Antigen presentation (MHC-I)\",\nL30:       \"definition\": \"The process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal proteins.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Immunopeptidome\",\nL34:       \"definition\": \"The collection of peptides presented by a tissue on MHC molecules, reflecting what the immune system can \"see\".\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"Would intratumoral mRNA vaccination improve ICI responses in a prospective randomized clinical trial?\",\nL39:     \"Which tumor types, disease stages, or prior treatments would be most likely to benefit from this strategy?\",\nL40:     \"What is the optimal timing of vaccination relative to starting checkpoint blockade to maximize benefit and safety?\",\nL41:     \"Could repeated intratumoral dosing maintain benefit without excessive inflammation or immune-related toxicity?\"\nL42:   ]\nL43: }",
            "callId": "call_8dJFzGyjJkaOnAMrOOTof897"
          }
        ],
        "usage": {
          "promptTokens": 8899,
          "cachedTokens": 4480,
          "responseTokens": 32,
          "thinkingTokens": 52,
          "totalTokens": 8983
        },
        "costUsd": 0.00969325
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Fixing JSON issues**\n\nI'm noticing that the public_summary has invalid JSON because of unescaped quotes in the immunopeptidome definition. I need to fix this and rewrite the file. I also need to ensure that the definition length is between 20 and 220 characters. I’ll replace \"see\" with the necessary escaped characters. After that, I should verify that other outputs are valid JSON, particularly focusing on claim_audit and such, but right now I'll concentrate on correcting the public_summary file.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may boost response to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting tumor control in some people, but many tumors do not respond because they are not well recognized by the immune system. This study asks whether putting an mRNA vaccine directly into a tumor can trigger a strong local innate immune reaction—especially type I interferon signaling—that makes the tumor more visible to immune cells and more susceptible to anti-PD-L1 therapy. In mouse tumor models, the authors report that intratumoral mRNA vaccination broadens the set of tumor-derived peptides presented on MHC-I and increases signs of immune activation. In a separate retrospective analysis of metastatic patients treated with ICIs, outcomes differed when patients were grouped by prior SARS-CoV-2 mRNA vaccination status during ICI treatment (reported p=0.01). Because the human data are retrospective and non-randomized, the work supports a mechanistic hypothesis but does not yet justify changes to clinical practice without prospective randomized trials.\",\n  \"what_is_new\": [\n    \"Links intratumoral mRNA vaccination to broader antigen presentation in tumors (immunopeptidome and MHC-I peptidome).\",\n    \"Proposes a mechanistic chain from type I interferon signaling to increased tumor visibility and PD-L1 pathway activity.\",\n    \"Adds a retrospective human cohort comparison stratified by prior SARS-CoV-2 mRNA vaccination status during ICI treatment.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so confounding could explain some or all of the survival difference.\",\n    \"Vaccination timing relative to ICI initiation varied, complicating interpretation of cause and effect.\",\n    \"Mouse model results may not translate directly to all human tumor types and treatment histories.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) so T cells can attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"Anti-PD-L1\",\n      \"definition\": \"A type of ICI antibody that targets PD-L1, aiming to restore anti-tumor T cell activity in the tumor environment.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of innate immune signaling molecules that can induce antiviral-like inflammation and alter antigen presentation in tissues.\"\n    },\n    {\n      \"term\": \"Antigen presentation (MHC-I)\",\n      \"definition\": \"The process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal proteins.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The collection of peptides presented by a tissue on MHC molecules, reflecting what the immune system can \\\"see\\\".\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would intratumoral mRNA vaccination improve ICI responses in a prospective randomized clinical trial?\",\n    \"Which tumor types, disease stages, or prior treatments would be most likely to benefit from this strategy?\",\n    \"What is the optimal timing of vaccination relative to starting checkpoint blockade to maximize benefit and safety?\",\n    \"Could repeated intratumoral dosing maintain benefit without excessive inflammation or immune-related toxicity?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_LoPlkxVixjIUNcaK8f4luMut"
          }
        ],
        "usage": {
          "promptTokens": 9685,
          "cachedTokens": 8576,
          "responseTokens": 829,
          "thinkingTokens": 74,
          "totalTokens": 10588
        },
        "costUsd": 0.016083550000000002
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 260
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccination inside tumors may boost response to checkpoint immunotherapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can lead to long-lasting tumor control in some people, but many tumors do not respond because they are not well recognized by the immune system. This study asks whether putting an mRNA vaccine directly into a tumor can trigger a strong local innate immune reaction—especially type I interferon signaling—that makes the tumor more visible to immune cells and more susceptible to anti-PD-L1 therapy. In mouse tumor models, the authors re\nL4:   \"what_is_new\": [\nL5:     \"Links intratumoral mRNA vaccination to broader antigen presentation in tumors (immunopeptidome and MHC-I peptidome).\",\nL6:     \"Proposes a mechanistic chain from type I interferon signaling to increased tumor visibility and PD-L1 pathway activity.\",\nL7:     \"Adds a retrospective human cohort comparison stratified by prior SARS-CoV-2 mRNA vaccination status during ICI treatment.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human analysis is retrospective and non-randomized, so confounding could explain some or all of the survival difference.\",\nL11:     \"Vaccination timing relative to ICI initiation varied, complicating interpretation of cause and effect.\",\nL12:     \"Mouse model results may not translate directly to all human tumor types and treatment histories.\",\nL13:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A cancer therapy that blocks inhibitory signals (checkpoints) so T cells can attack tumors more effectively.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"Anti-PD-L1\",\nL22:       \"definition\": \"A type of ICI antibody that targets PD-L1, aiming to restore anti-tumor T cell activity in the tumor environment.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Type I interferon\",\nL26:       \"definition\": \"A family of innate immune signaling molecules that can induce antiviral-like inflammation and alter antigen presentation in tissues.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"Antigen presentation (MHC-I)\",\nL30:       \"definition\": \"The process where cells display peptide fragments on MHC-I molecules so CD8+ T cells can recognize abnormal proteins.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Immunopeptidome\",\nL34:       \"definition\": \"The collection of peptides presented by a tissue on MHC molecules, reflecting what the immune system can \\\"see\\\".\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"Would intratumoral mRNA vaccination improve ICI responses in a prospective randomized clinical trial?\",\nL39:     \"Which tumor types, disease stages, or prior treatments would be most likely to benefit from this strategy?\",\nL40:     \"What is the optimal timing of vaccination relative to starting checkpoint blockade to maximize benefit and safety?\",\nL41:     \"Could repeated intratumoral dosing maintain benefit without excessive inflammation or immune-related toxicity?\"\nL42:   ]\nL43: }",
            "callId": "call_eBfad7DfjPRtiFzv0yfNIwZv"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 220
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory tumor state that improves sensitivity to immune checkpoint blockade (anti-PD-L1)?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Murine tumor models treated with intratumoral mRNA vaccine in combination with anti-PD-L1, pooled across repeat experiments to assess anti-tumor efficacy.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-controls\",\nL19:       \"label\": \"Mouse control cohort (single agents/vehicle)\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched murine controls including vaccine only, ICI only, and vehicle arms pooled across experiments to benchmark baseline activity and specificity of effects.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective cohort of metastatic patients receiving immune checkpoint inhibitor treatment, stratified by prior SARS-CoV-2 mRNA vaccination status for outcome comparison.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used for survival comparison under ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for survival under ICI treatment.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"Human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_6OuOnR9QOU2QnJiT8HCHXSkt"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 260
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Intratumoral mRNA vaccination is associated with broader antigen display in the tumor immunopeptidome.\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"The MHC-I-presented peptide landscape expands substantially after intratumoral mRNA vaccination.\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"In the retrospective cohort, vaccinated patients had statistically improved survival under ICI treatment.\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Tumors show a marked induction of a type I interferon response after mRNA vaccination.\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"PD-L1 pathway activity increases, supporting a mechanistic rationale for checkpoint blockade combination.\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Combination therapy increases CD8+ T-cell infiltration relative to baseline.\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "call_eQC39iEeqtLfm02YyAU7ml9G"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 260
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination induces type I interferon signaling and is associated with expanded antigen presentation on MHC-I.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\nL14:           \"line_ref\": \"L29\"\nL15:         },\nL16:         {\nL17:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL18:           \"line_ref\": \"L44\"\nL19:         }\nL20:       ],\nL21:       \"caveat\": \"The report summarizes mechanistic steps, but notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL22:     },\nL23:     {\nL24:       \"claim_id\": \"C02\",\nL25:       \"claim\": \"The combined intervention improves tumor control in mice and aligns with better outcomes in a retrospective human cohort stratified by SARS-CoV-2 mRNA vaccination status.\",\nL26:       \"strength\": \"moderate\",\nL27:       \"evidence\": [\nL28:         {\nL29:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\nL30:           \"line_ref\": \"L46\"\nL31:         },\nL32:         {\nL33:           \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\nL34:           \"line_ref\": \"L30\"\nL35:         },\nL36:         {\nL37:           \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\nL38:           \"line_ref\": \"L15\"\nL39:         }\nL40:       ],\nL41:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, so alignment with better outcomes does not establish causality.\"\nL42:     },\nL43:     {\nL44:       \"claim_id\": \"C03\",\nL45:       \"claim\": \"The reported sensitization effect is conditional on the mRNA-triggered type I interferon pathway, based on particle controls and IFNAR1 blockade results.\",\nL46:       \"strength\": \"strong\",\nL47:       \"evidence\": [\nL48:         {\nL49:           \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL50:           \"line_ref\": \"L38\"\nL51:         },\nL52:         {\nL53:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL54:           \"line_ref\": \"L39\"\nL55:         }\nL56:       ],\nL57:       \"caveat\": \"These perturbation controls are described in the report, but the overall findings are from preclinical systems and may not map one-to-one to all human tumors.\"\nL58:     },\nL59:     {\nL60:       \"claim_id\": \"C04\",\nL61:       \"claim\": \"Prospective randomized studies are required before changing clinical protocols based on the reported tumor-sensitization effects.\",\nL62:       \"strength\": \"strong\",\nL63:       \"evidence\": [\nL64:         {\nL65:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL66:           \"line_ref\": \"L49\"\nL67:         },\nL68:         {\nL69:           \"quote\": \"The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.\",\nL70:           \"line_ref\": \"L55\"\nL71:         }\nL72:       ],\nL73:       \"caveat\": \"This is a cautious interpretive conclusion; it does not quantify how large a benefit would be expected in a future randomized trial.\"\nL74:     }\nL75:   ]\nL76: }",
            "callId": "call_Nbj1B0F87KKyGiZdyfjZDpem"
          }
        ],
        "usage": {
          "promptTokens": 10528,
          "cachedTokens": 4480,
          "responseTokens": 131,
          "thinkingTokens": 0,
          "totalTokens": 10659
        },
        "costUsd": 0.013202
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "text": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
        "thoughts": "**Verifying JSON validity**\n\nI need to ensure the JSON is valid for study_overview, claim_audit, and public_summary, which is now fixed. We should verify that public_summary's plain language summary fits the length requirement of 180-1200 characters, likely around 650. The headline length should also be between 20-120 characters, which seems good. I've already rewritten public_summary due to the previous JSON issue. Now, I'll follow the rule to finish after writing the required files and have valid JSON, while avoiding loops. I’ll respond with a checklist.",
        "toolCalls": [],
        "usage": {
          "promptTokens": 14095,
          "cachedTokens": 9600,
          "responseTokens": 53,
          "thinkingTokens": 90,
          "totalTokens": 14238
        },
        "costUsd": 0.01154825
      }
    ],
    "totalCostUsd": 0.15132530000000002
  }
}
